Market Cap (In USD)
4.79 Million
Revenue (In USD)
-
Net Income (In USD)
-7 Million
Avg. Volume
815.99 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.77-4.17
- PE
- -0.27
- EPS
- -2.72
- Beta Value
- 1.296
- ISIN
- US00688A2050
- CUSIP
- 00688A106
- CIK
- 1513525
- Shares
- 6574590.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Cary John Claiborne MBA
- Employee Count
- -
- Website
- https://www.adialpharma.com
- Ipo Date
- 2018-07-27
- Details
- Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
More Stocks
-
2186Sobal Corporation
2186
-
2351ASJ Inc.
2351
-
5884KURADASHI.Co.,Ltd.
5884
-
4382HEROZ, Inc.
4382
-
EZGO
-
COG
-
NSGCFNorthstar Gold Corp.
NSGCF
-
LTRE